Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Japan Blood Products Organization to Begin Operations in October: JRCS, MTPC
May 10, 2012
- Once-Monthly Abilify Significantly Extends Time to Relapse in Adult Schizophrenia Patients: Otsuka
May 10, 2012
- Shionogi’s US Subsidiary Submits NDA for VVA Treatment Ospemifene in the US
May 10, 2012
- Bayer, Santen to Copromote VEGF Trap-Eye Injection
May 10, 2012
- Daiichi Sankyo Ties Up with Coherus BioSciences to Embark on Biosimilars Business
May 9, 2012
- Sanofi-aventis Initiates PIII Trial for Hydroxychloroquine for SLE, CLE
May 9, 2012
- Kyowa Medex Launches Companion Diagnostics of Poteligeo
May 9, 2012
- VIVUS Receives Approval for ED Treatment in the US: MTPC
May 9, 2012
- All-Case Surveillance Lifted for Remicade for Psoriasis: MTPC
May 9, 2012
- Roche to Discontinue Development of JT’s Dyslipidemia Treatment Dalcetrapib
May 9, 2012
- Takeda Goes to Tax Tribunal Demanding Cancellation of All Transfer Pricing Taxes on Prevacid
May 9, 2012
- CMIC, Medipal Set Up OrphanPacific, to Collaborate for New Business Model
May 8, 2012
- Former Novartis Pharma’s Head of Sales to Become NBI President
May 8, 2012
- Sales Increase by 9.9%, Net Profits Return to Black: NBI
May 8, 2012
- OrphanPacific Focuses on Building Detailing Form: President Ichikawa
May 8, 2012
- Eisai US Subsidiary Concludes Research Agreement with UK Venture for Identifying Target Molecules for New Cancer Drugs
May 8, 2012
- Daiichi Sankyo to Aim for Early Market Penetration for Ranmark in Copromotion with AZ
May 7, 2012
- The Growing Presence of Foreign-Affiliates (1)
May 7, 2012
- GSK Files Ofatumumab for Treatment of CLL
May 7, 2012
- DSP Aims to Enhance Its Presence in Field of Oncology by Developing First-in-Class Drugs
May 7, 2012
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…